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Summary  In  heart  failure,  it  has  been  recognized  that  the  sympathetic  nervous  system  (SNS)
is activated  and  the  imbalance  of  the  activity  of  the  SNS  and  vagal  activity  interaction  occurs.
The abnormal  activation  of  the  SNS  leads  to  further  worsening  of  heart  failure.  Many  previous
clinical and  basic  studies  have  demonstrated  that  the  abnormal  activation  of  the  SNS  is  caused
by the  enhancement  of  excitatory  inputs  including  changes  in:  (1)  peripheral  baroreceptor
and chemoreceptor  reﬂexes;  (2)  chemical  mediators  that  control  sympathetic  outﬂow;  and
(3) central  sites  that  integrate  sympathetic  outﬂow.  In  particular,  the  abnormalities  in  central
SNS regulation  due  to  the  renin  angiotensin  system—oxidative  stress  axis  have  recently  been
in focus.  In  the  treatment  of  heart  failure,  the  inhibition  of  the  activated  SNS,  such  as  with
beta-blockers  and/or  exercise  training,  is  important.  Furthermore,  many  experimental  studies
have demonstrated  that  vagal  stimulation  has  beneﬁcial  effects  on  heart  failure,  and  recently
several clinical  studies  have  also  demonstrated  that  vagal  stimulation  is  a  possible  novel  therapy
for heart  failure.  In  conclusion,  we  must  recognize  that  heart  failure  is  a  complex  syndrome
with an  autonomic  nervous  system  dysfunction,  and  that  the  autonomic  imbalance  with  the
activation  of  the  SNS  and  the  reduction  of  vagal  activity  should  be  treated.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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he  sympathetic  nervous  system  (SNS)  has  a  wide  variety
f  cardiovascular  actions,  including  heart  rate  acceleration,
ncrease  in  cardiac  contractility,  reduction  of  venous  capac-
tance,  and  constriction  of  resistance  vessels  [1,2]. On  the
ontrary,  the  vagal  activity  affects  the  cardiovascular  sys-
em  by  slowing  heart  rate  [3].  The  cardiac  sympathetic
erve  ﬁbers  are  located  at  sub-epicardium  and  travel  along
he  major  coronary  arteries  representing  the  predominant
utonomic  component  in  the  ventricles  [1,2]. The  parasym-
athetic  ﬁbers  run  with  the  vagal  nerve  at  sub-endocardium
fter  it  crosses  the  atrial—ventricular  groove  and  are  mainly
resent  in  the  atrial  myocardium  and  less  abundantly  in
he  ventricular  myocardium  [4].  The  sympathetic  outﬂow
o  the  heart  and  peripheral  circulation  is  regulated  by  car-
iovascular  reﬂex  [1,2]. Afferent  ﬁbers  are  usually  carried
oward  the  central  nervous  system  by  autonomic  nerves,
hereas  efferent  ﬁbers  travel  from  the  central  nervous
ystem  toward  different  organs  either  in  autonomic  or
omatic  nerves  [1,2]. The  main  reﬂex  responses  originate
rom  aortic  arch  and  carotid  baroreceptors  (SNS  inhibition),
ardiopulmonary  baroreceptors  (diverse  reﬂexes  including
he  Bezold—Jarisch  reﬂex,  SNS  inhibition),  cardiovascular-
ow  threshold  poly-modal  receptors  (SNS  activation),  and
eripheral  chemoreceptors  (SNS  activation)  [4].
This  article  reviews  the  autonomic  imbalance  of  the  acti-
ation  of  the  SNS  and  the  reduction  of  vagal  activity,  which
s  known  to  lead  to  further  worsening  of  the  prognosis  for
eart  failure.  Furthermore,  in  this  article,  we  focus  on  the
ecent  concept  of  treatments  targeting  autonomic  nervous
ystem  dysfunction.
ympathetic hyperactivity in heart failure —
linical research
n  systolic  dysfunction,  neuronal  and  humoral  hyperactiv-
ty  occur  to  preserve  cardiac  output  [1,2]. The  neuronal
esponse  is  the  activation  of  the  SNS  and  the  reduc-
ion  of  vagal  activity,  and  the  humoral  response  is  the
ncrease  in  secretion  of  certain  hormones,  such  as  the
enin—angiotensin—aldosterone  axis  [5].  In  heart  failure
ith  preserved  left  ventricular  ejection  fraction  (dias-
olic  heart  failure),  there  is  limited  information  regarding
hronic  SNS  activation  [6].  However,  the  ﬁndings  of  a
ecent  study  indicate  that,  in  patients  with  hyperten-
ion,  SNS  hyperactivity  (increased  muscle  sympathetic  nerve
rafﬁc)  may  contribute  to  the  development  of  left  ventric-
lar  diastolic  dysfunction  and  accounts  for  the  increased
ardiovascular  risk  [7].  The  SNS  hyperactivity  observed
n  heart  failure  is  closely  related  to  abnormalities  in
ardiovascular  reﬂexes  [1,2]. The  sympathoinhibitory  car-
iovascular  reﬂexes  such  as  the  arterial  baroreceptor  reﬂex
t
s
c
are  signiﬁcantly  suppressed,  whereas  the  sympathoexcita-
ory  reﬂexes,  including  the  cardiac  sympathetic  afferent
eﬂex  and  the  arterial  chemoreceptor  reﬂex,  are  augmented
8].  These  abnormalities  in  cardiovascular  reﬂexes  are  con-
idered  to  increase  the  activity  of  the  SNS  in  heart  failure,
nd  heart  failure  due  to  left  ventricular  systolic  dysfunction
as  long  been  considered  a  state  of  generalized  activation  of
he  SNS  to  alter  cardiac  and  peripheral  hemodynamics  that
s  initially  appropriate,  but  ultimately  pathological  [2].
However,  it  is  now  recognized  that:  (1)  the  time  course
nd  magnitude  of  the  activation  of  the  SNS  are  target
rgan-speciﬁc,  not  generalized,  and  independent  of  ven-
ricular  systolic  function;  and  (2)  human  heart  failure
s  characterized  by  rapidly  responsive  arterial  baroreﬂex
egulation  of  muscle  sympathetic  nerve  activity  (MSNA),
ttenuated  cardiopulmonary  reﬂex  modulation  of  MSNA,  a
ardiac  sympathoexcitatory  reﬂex  related  to  increased  car-
iopulmonary  ﬁlling  pressure,  and  by  individual  variation  in
onbaroreﬂex-mediated  sympathoexcitatory  mechanisms,
ncluding  coexisting  sleep  apnea,  myocardial  ischemia,  obe-
ity,  and  reﬂexes  from  exercising  muscle  [2]  (Fig.  1).  Thus,
he  activation  of  the  SNS  in  the  setting  of  impaired  systolic
unction  reﬂects  the  net  balance  and  interaction  between
ppropriate  reﬂex  compensatory  responses  to  impaired  sys-
olic  function  and  excitatory  stimuli  that  elicit  adrenergic
esponses  in  excess  of  homeostatic  requirements  [2].
In  human  heart  failure,  a  previous  study  has  demon-
trated  that  signiﬁcant  increases  in  internal  jugular  venous
pillover  of  metabolites  of  norepinephrine  and  epinephrine,
ith  a  positive  correlation  between  brain  norepinephrine
urnover  and  cardiac  norepinephrine  spillover  [2].  These
esults  suggest  that  activation  of  noradrenergic  neurons  pro-
ecting  from  the  brain  stem  mediates  the  activity  of  the
NS,  and  that  the  central  abnormalities  have  the  possibil-
ty  to  activate  the  SNS  in  heart  failure.  The  mechanisms  in
hich  the  central  abnormalities  occur  in  heart  failure  have
ot  been  fully  determined  in  clinical  studies,  and  it  has  not
een  also  fully  determined  whether  the  central  abnormali-
ies  are  caused  by  neuronal  input  or  humoral  factors.  Further
linical  novel  studies  are  necessary.
ympathetic hyperactivity in heart failure  —
asic research
xperimental  models  of  heart  failure,  together  with  clini-
al  data,  have  solidly  established  that  sympathoexcitation
nd  an  abnormal  cardiovascular  reﬂex  function  contribute
o  the  activation  of  the  SNS  in  heart  failure  [9].  In
nimal  studies,  the  primary  mechanism  in  the  activa-
ion  of  the  SNS  is  also  the  reduced  sensitivity  of  various
ympathoinhibitory  reﬂexes  (e.g.  arterial  baroreﬂex  and
ardiopulmonary  reﬂexes)  [10]. Furthermore,  circulating
nd  local  hormonal  factors  [angiotensin  II,  nitric  oxide
HF  and  autonomic  dysfunction  119
Figure  1  Mechanisms  of  the  activation  of  the  sympathetic  nervous  system  in  heart  failure  (modiﬁed  from  reference  [2]). Afferent
inputs from  the  arterial  chemoreceptors,  cardiopulmonary  baroreceptors,  and  muscle  metaboreceptors  are  activated,  and  affer-
ent inputs  from  arterial  baroreceptors,  ventricular  mechanoreceptors,  and  pulmonary  receptors  are  inhibited.  Central  excitatory
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mmechanisms are  activated.  Efferent  mechanisms  increase  norepi
central nervous  system;  E,  epinephrine.
(NO),  reactive  oxygen  species  (ROS),  arginine  vasopressin,
endothelin-1,  atrial  natriuretic  peptide,  prostaglandins,  and
aldosterone]  are  considered  to  modulate  sympathetic  out-
ﬂow  at  several  sites  in  the  central  nervous  system.  In
addition,  more  recent  data  show  direct  central  effects  of
pro-inﬂammatory  cytokines  on  the  activity  of  SNS  [10—14].
The  central  nervous  system  receives  inputs  from  a  vari-
ety  of  sources  in  the  body  and  activates  mechanisms  that
play  a  major  role  in  progressive  cardiac  remodeling  and
dysfunction  [15]. For  example,  it  has  been  demonstrated
that  the  angiotensin  II  and  aldosterone  produced  locally
in  the  brain  affect  SNS  activation  and  progression  of  sys-
tolic  heart  failure  [16]. Angiotensin  II  type  1  receptors
are  found  throughout  the  central  nervous  system  and  are
expressed  to  a  high  degree  in  areas  of  the  hypothalamus
and  medulla,  which  regulate  sympathetic  outﬂow  [17]. It
has  already  been  demonstrated  that  angiotensin  II  initiates
a  positive  feedback  mechanism  leading  to  up-regulation  of
the  angiotensin  II  type  1  receptor,  nitric  oxide  inhibition,  and
increased  production  of  superoxide  anion  through  the  action
of  nicotinamide  adenine  dinucleotide  phosphate  (NAD(P)H)
oxidase,  leading  to  increased  sympathetic  outﬂow  and  pro-
gression  in  heart  failure  [10,13,14,18]. Previous  studies  have
shown  increases  in  angiotensin  II  type  1  receptor  protein,
mRNA,  and  angiotensin  II  binding  in  the  rostral  ventrolat-
eral  medulla  (RVLM)  and  the  nucleus  tractus  solitarii  (NTS)
in  rabbits  and  rats  with  heart  failure  [10,19,20]. Further-
more,  The  balance  between  angiotensin-converting  enzyme
(ACE)  and  its  homolog  ACE2  or  between  angiotensin  II  type
1  and  2  receptor  in  the  brain  may  be  an  important  determi-
nant  of  sympathoexcitation  in  heart  failure  [10,19,21,22].
Especially,  in  the  brain,  RVLM  is  well  known  as  a  vasomo-
tor  center,  and  it  is  well  established  that  the  angiotensin
II  type  1  receptor-induced  ROS  via  NAD(P)H  oxidase  in  the
RVLM  activates  the  SNS  through  the  transcriptional  pathways
[12,13].  These  mechanisms  in  the  RVLM  are  also  considered
m
(
e
(rine  (NE)  release  and  alter  NE  uptake.  Ach,  acetylcholine;  CNS,
o  play  a major  role  in  activating  the  SNS  in  heart  failure
10,14,19,20].  The  angiotensin  II  type  1  receptor-induced
OS  via  NAD(P)H  oxidase  in  the  RVLM  might  be  a  novel  target
f  therapy  for  heart  failure  through  sympathoinhibition.
arasympathetic dysfunction in heart failure
cute  myocardial  ischemia  represents  a  very  useful  model
or  a  clear  representation  of  what  may  appear  as  a  com-
lex  relationship  between  sympathetic  and  vagal  activity.
he  sensory  endings  of  both  vagal  and  sympathetic  afferent
bers  are  mechanoreceptors  and  are  thereby  stimulated  by
he  mechanical  stretching  associated  with  cardiac  dilation
4].  Indeed,  when  the  heart  dilates,  vagal  and  sympathetic
fferent  cardiac  ﬁbers  increase  their  ﬁring,  and  this  afferent
ympathetic  excitation  leads  to  the  tonic  and  reﬂex  inhibi-
ion  of  cardiac  vagal  efferent  activity  [4].  This  phenomenon
an  be  expected  to  occur  whenever  the  heart  dilates  in  heart
ailure  probably  due  to  the  systolic  dysfunction.  In  cases  of
iastolic  dysfunction  in  which  the  heart  does  not  dilate,  the
echanisms  in  which  the  vagal  activity  is  reduced  have  not
een  fully  determined.
herapy — sympathoinhibition
eta-blockers  can  be  broadly  classiﬁed  into  generations:  (1)
rst  generation,  which  are  nonselective  and  competitively
lock  both  the  beta1-  and  beta2-receptors  (propranolol,
adolol,  timolol);  (2)  second  generation,  with  much  higher
fﬁnity  for  the  beta1-  than  for  the  beta2-receptor  (atenolol,
etoprolol,  bisoprolol);  and  (3)  third  generation,  which
ay  be  selective  (celiprolol,  nebivolol)  or  nonselective
bucindolol,  carvedilol,  labetalol)  but  all  cause  periph-
ral  vasodilation  mediated  via  alpha1-receptor  blockade
bucindolol,  carvedilol,  labetalol),  beta2-receptor  agonism
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Figure  2  Effect  of  vagal  nerve  stimulation  (Stim.)  on  survival
curves of  rats  with  heart  failure  treated  with  sham  and  vagal
stimulation.  Treatment  started  14  days  after  coronary  artery
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celiprolol),  or  nitric  oxide  synthesis  (nebivolol)  [23]. Among
ll  beta-blockers,  bisoprolol  (except  in  the  USA),  carvedilol,
nd  metoprolol  succinate  (except  in  Canada)  are  almost
niversally  approved  for  the  treatment  of  chronic  heart
ailure  [24—29]. Chronic  beta-blocker  therapy  improves
eft  ventricular  performance  and  reverses  left  ventricular
emodeling,  reduces  risk  of  hospitalization,  and  improves
urvival  [24—29].
In the  Veterans  Administration  Cooperative  Study,  the
atients  with  heart  failure  receiving  the  alpha1-blocker,  pra-
osin,  experienced  worse  outcomes  than  did  those  receiving
he  combined  vasodilator  therapy  of  hydralazine  and  isosor-
ide  dinitrate  [30]. Chronic  use  of  prazosin  has  been
eported  to  increase  catecholamine  levels,  diminishing  any
otentially  beneﬁcial  action  mediated  through  inhibition  of
he  alpha1-receptor  [31]. In  the  ALLHAT  (Antihypertensive
nd  Lipid-Lowering  Treatment  to  Prevent  Heart  Attack  Trial)
tudy  (ALLHAT  collaborative),  the  other  alpha1-blocker,  dox-
zosin,  was  terminated  early  because  of  the  higher  heart
ailure  incidence  [32].
Central  alpha2  receptor  has  been  considered  to  be  a
ossible  target  of  treatment  for  heart  failure,  because
he  excitation  of  the  central  alpha2  receptor  inhibits  the
ctivation  of  the  SNS  [33]. Clonidine  is  a  centrally  act-
ng  agent  with  alpha2-agonist  actions.  In  modest  doses
f  clonidine,  it  signiﬁcantly  attenuates  cardiac  and  renal
ympathetic  tone  in  patients  with  heart  failure  [34]. Inter-
stingly,  chronic  clonidine  administration  exerted  marked
ympathoinhibitory  effects  without  further  clinical  deteri-
ration  in  a  small  and  short-term  clinical  study  [34]. Large
linical  trials  are  needed  to  evaluate  the  beneﬁts.  The  other
entrally  acting  sympathoinhibitry  agent,  moxonidine,  acts
hrough  both  alpha2-  and  imidazoline  receptors  [35]. How-
ver,  in  clinical  trials,  moxonidine  led  to  increased  mortality
36].
Angiotensin  II  and  aldosterone  production  enhance  the
elease  and  inhibit  the  uptake  of  norepinephrine  at  nerve
ndings  [37]. ACE  inhibitors  have  a  predictable  effect  in
ncreasing  plasma  renin  and  decreasing  angiotensin  II  and
ldosterone  levels,  whereas  norepinephrine  and  vasopressin
eduction  is  attributed  to  the  hemodynamic  improvement
38]. It  should  be  determined  whether  angiotensin  II  type
 receptor  blockers  have  also  the  beneﬁcial  effects  on  the
ympathetic  hyperactivity  in  heart  failure  or  not.  Plasma
ldosterone  levels  may  be  elevated  as  high  as  20-fold  in
atients  with  heart  failure,  primarily  due  to  increased  pro-
uction  by  the  adrenal  glands  following  stimulation  by  the
igh  plasma  angiotensin  II  concentrations.  A  previous  large
linical  trial  has  already  shown  the  beneﬁt  with  aldosterone
ntagonists  in  heart  failure  patients  and  this  may  be  partially
elated  to  their  effect  on  norepinephrine  [39].
Exercise  intolerance  is  a  characteristic  of  patients  with
hronic  heart  failure,  and  skeletal  myopathy  contributes
o  the  limitation  of  functional  capacity  in  heart  failure
1,2].  The  activation  of  SNS  and  myogenic  reﬂex  engagement
oderate  the  heart  and  muscle  vasculature  to  maintain
dequate  blood  pressure  during  exercise  [40]. However,
bnormal  activation  of  the  SNS  contributes  to  the  skele-
al  myopathy  seen  in  heart  failure,  because  SNS-mediated
asoconstriction  at  rest  and  during  exercise  restrains  mus-
le  blood  ﬂow,  arteriolar  dilation,  and  capillary  recruitment,
eading  to  underperfusion,  ischemia,  release  of  ROS,  and
[
s
i
tigation.  Vagal  stimulation  signiﬁcantly  improved  survival  rate
modiﬁed  from  reference  [45]).
hronic  inﬂammation  [41]. Interestingly,  current  evidence
uggests  that  exercise  training  improves  central  hemody-
amics,  peripheral  muscle  function,  and  symptoms  and
educes  the  activity  of  the  SNS  even  in  patients  treated
ith  beta-blockers  [42]. The  HF-ACTION  (Heart  Failure  —  A
andomized  Controlled  Trial  Investigating  Outcomes  of  exer-
ise  traiNing)  study,  the  ﬁrst  large,  randomized,  controlled
rial  to  evaluate  the  effects  of  exercise  training  in  heart
ailure  patients,  demonstrated  that  exercise  training  is  safe
nd  offers  clinical  beneﬁts  in  this  patient  population  [43].
he  mechanisms  for  these  beneﬁcial  effects  of  exercise  in
eart  failure  patients  proposed  include:  (1)  improvement  in
rterial  and  chemoreﬂex  control;  (2)  signiﬁcant  reduction
n  central  sympathetic  outﬂow;  (3)  correction  of  central
ervous  system  abnormalities;  (4)  increase  in  peripheral
lood  ﬂow;  (5)  reduction  of  circulating  cytokines;  and  (6)
ncrease  in  muscle  mass  [44]. Experimental  evidence  sug-
ests  that  the  exercise  training-induced  beneﬁcial  effects
n  autonomic  activity  in  heart  failure  may  be  due  to  an
p-regulation  in  central  antioxidative  mechanisms  and  sup-
ressed  central  pro-oxidant  mechanisms  [21].
herapy — vagal stimulation
hronic  electrical  vagal  stimulation  has  been  assessed  in
everal  animal  studies.  Rats  with  heart  failure  post  myocar-
ial  infarction  randomized  to  vagal  stimulation  showed
igniﬁcant  improvement  in  left  ventricular  hemodynamics
nd  decreased  mortality  from  50%  to  14%  in  140  days  [45]
Fig.  2).  In  another  study,  therapy  with  vagal  nerve  elec-
rical  stimulation  combined  with  beta-blockade  improved
eft  ventricular  systolic  function  beyond  that  seen  with
eta-blockers  alone  [46]. More  recently,  Zhang  et  al.  demon-
trated  that  animals  in  the  vagal  stimulation  group  had
igniﬁcantly  lower  left  ventricular  end-diastolic  and  end-
ystolic  volumes  and  higher  left  ventricular  ejection  fraction
47]. These  experimental  studies  suggest  that  chronic  vagal
timulation  might  have  signiﬁcant  positive  effects  in  the  fail-
ng  heart  and  heart  failure.  Interestingly,  they  also  suggest
he  important  concept  that  the  mechanism(s)  underlying  the
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protective  effect  of  vagal  stimulation  involve  something  at
least  in  part  independent  of  the  heart  rate  slowing.
In  several  clinical  studies,  favorable  ﬁndings  on  quality
of  the  New  York  Heart  Association  class,  quality  of  life,  and
6  min  walk  test  were  conﬁrmed  and  a  signiﬁcant  decrease
in  left  ventricular  end-systolic  volume  and  a  signiﬁcant
increase  in  left  ventricular  ejection  fraction  are  indicated
[48,49].  A  large  controlled  multicenter  study  for  USA  and
Europe  is  expected  to  provide  soon  a  more  precise  deﬁnition
of  the  role  of  vagal  stimulation  in  heart  failure.
Summary and future prospects
In  heart  failure,  it  has  been  recognized  that  autonomic  ner-
vous  system  dysfunction  occurs.  In  the  treatment  of  heart
failure,  the  inhibition  of  the  activated  SNS,  such  as  with
beta-blockers  and/or  exercise  training,  is  important.  Fur-
thermore,  it  has  recently  been  demonstrated  that  vagal
stimulation  has  beneﬁcial  effects  on  heart  failure.  We  must
recognize  that  heart  failure  is  a  complex  syndrome  with
an  autonomic  nervous  system  dysfunction,  and  that  the
autonomic  imbalance  with  the  activation  of  SNS  and  the
reduction  in  vagal  activity  should  be  focused  on  more  in
the  aspects  of  treatment  for  heart  failure.  In  this  aspect,
conservative  pharmacological  therapy  is  not  sufﬁcient,  and
device  therapy  and/or  non-pharmacological  therapy  (exer-
cise  training,  Waon-therapy  [50]) are  necessary.
The  mechanisms  by  which  autonomic  nervous  system
dysfunction  occurs  in  heart  failure  have  not  been  fully  deter-
mined.  Especially,  the  central  abnormalities  need  further
examination  in  clinical  and  basic  research.  How  does  the
brain  ‘‘recognize’’  the  condition  of  ‘‘heart  failure’’?  What
is  the  input  into  the  brain,  neuronal  or  humoral  factors?  The
answers  to  these  questions  will  contribute  to  a  new  and
novel  concept  for  the  treatment  of  heart  failure,  ‘‘brain
is  a  major  target  in  the  treatment  of  heart  failure  through
sympathoinhibition’’.
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